*In a Phase 3, randomised, open-label study comparing CABOMETYX (n=330) with everolimus (n=328) in adult patients with aRCC progressing after prior anti-VEGF therapy.33
CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC)6:
- in treatment-naïve adults with intermediate or poor risk per IMDC criteria
- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
1L: First-Line, 2L: Second-Line, CI: Confidence Interval, HR: Hazard Ratio, IMDC: International Metastatic Renal Cell Carcinoma Database, OS: Overall Survival, TKI: Tyrosine Kinase Inhibitor.